The role of endothelin receptor antagonists in IgA nephropathy

Mitchell Hunter-Dickson; Muh Geot Wong

doi:10.1111/nep.14364

The role of endothelin receptor antagonists in IgA nephropathy

Nephrology (Carlton). 2024 Sep:29 Suppl 2:30-33. doi: 10.1111/nep.14364.

Authors

Mitchell Hunter-Dickson¹, Muh Geot Wong^{1

2}

Affiliations

¹ Department of Renal Medicine, Concord Repatriation General Hospital, Concord, New South Wales, Australia.
² Concord Clinical School, University of Sydney, Concord, New South Wales, Australia.

PMID: 39327742
DOI: 10.1111/nep.14364

Abstract

There is growing evidence of endothelin receptor antagonists (ERAs) in renoprotection in proteinuric kidney disease including IgA nephropathy (IgAN). Here, we review current evidence, including the use of sparsentan, atrasentan and zibotentan in IgAN. Recent trails of combination therapy including SGLT2 inhibitors and ERAs suggest possible benefit in further reduction of proteinuria and reducing ERA fluid-retention side effects although more evidence is needed for clinical applications.

Keywords: IgA; endothelin; proteinuria.

Publication types

Review

MeSH terms

Endothelin Receptor Antagonists* / therapeutic use
Glomerulonephritis, IGA* / drug therapy
Humans
Proteinuria / drug therapy
Treatment Outcome

Substances

Endothelin Receptor Antagonists